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INTRODUCTION 
The lack of federal cosmetics regulation by the U.S. Food and 
Drug Administration (FDA) under the Federal Food, Drug, and Cos-
metic Act (FD&C Act) has a disparate impact on women. The scarcity 
of federal cosmetics regulation and its biased effect on women are 
further accentuated when viewed in comparison to the extent of the 
FD&C Act's food and drug regulations, as well as in light of cosmetics 
research and reports conducted over the past eighty years. Statistics 
show that women use more cosmetic products than men overall.1 
1. See, e.g., Rebecca Adams, This Is Why It's More Expensive to Be a Woman, HUFFING-
TON POST (Sept. 23, 2013), http://www.huffingtonpost.com/2013/09/23/beauty-products 
_n_3975209.html [https://perma.ccJLB23-3AQE]. 
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The lack of federal cosmetics regulation thus results in the FD&C 
Act being gender-biased by not offering the users of cosmetic prod-
ucts (i.e., women) the same protections provided to both men and 
women in the regulation of the FD&C Act's other two jurisdictional 
industries-food and drugs.2 
Part I of this Note analyzes the FD&C Act provisions regulating 
cosmetics and contrasts them with the far more extensive regula-
tions over food and drugs. It also explores the legislative history of 
the FD&C Act in an attempt to answer the question of why there is 
comparatively so little federal cosmetics regulation. Part II takes an 
in-depth look at cosmetics-what they are, how they affect women 
as their core users more so than men, and the limited legal remedies 
that exist. Part III then argues the lack of cosmetics regulation under 
the FD&C Act results in a disparate impact on women as cosmetic 
products' main users, which must be remedied with new federal 
cosmetics legislation. Finally, Part IV asserts the claim that the 
gender bias stemming from this lack of cosmetics regulation under 
the FD&C Act is not cured by the cosmetic industry's self-regula-
tion, and instead requires additional provisions to be amended to 
the cosmetics subchapter of the FD&C Act. This final part explores 
three pieces oflegislation that are currently in front of Congress and 
the industry's response to their provisions. 
I. CONTRASTING COSMETICS REGULATION IN THE FD&C 
ACT TO THAT OF FOOD AND DRUGS TO ESTABLISH A 
LACK OF COSMETICS REGULATION 
A. Federal Food, Drug, and Cosmetic Act Regulation of Cosmetics 
Versus its Regulation of Food and Drugs 
The scope of cosmetics regulation under the FD&C Act is far less 
expansive than regulations of both food and drugs, which captures 
more nuances in those industries than the cosmetics subchapter. 3 
Cosmetics regulation spans a mere three sections of the entire Act: 
(1) what constitutes an adulterated cosmetic, (2) what constitutes a 
misbranded cosmetic, and (3) a note on regulations making exemp-
tions to any aforementioned cosmetic labeling requirement. 4 These 
2. Compare 21 U.S.C.A. §§ 361-63 (West 1993) (cosmetic regulations under FD&C 
Act), with 21 U.S.C.A. §§ 341-501-1 (West 1993) (food regulations under FD&C Act), and 
21 U.S.C.A. §§ 351-60fff-7 (West 2017) (drug regulations under FD&C Act). 
3. Compare21 U.S.C.A. §§ 361-63 (West 1993), with 21 U.S.C.A. §§ 341-501-1 (West 
1993); see also 21 U.S.C.A. 351-60fff-7 (West 2017). 
4. 21 U.S.C.A. §§ 361-63. 
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sections are not extensive: the longest section, the misbranding pro-
vision, contains only six subsections, which are each only-at most-
several lines long. 5 Perhaps most notably absent are provisions 
outlining any FDA approval or notification processes for cosmetic 
products and their ingredients,6 other than requiring pre-market 
approval for color additives contained in cosmetics. 7 
Analyzing the provisions regulating food and drugs under the 
FD&C Act further emphasizes the major deficiency in federal cos-
metics regulation.8 The FD&C Act's subchapter on food contains 
twenty-seven sections in addition to three sections analogous to those 
regulating cosmetics.9 The food adulteration and misbranding pro-
visions are also more comprehensive with many more definitions 
and nuances.10 The presence of over two dozen additional sections 
provides more guidance and awareness of the law and further demon-
strates the depth of regulation that the FDA via the FD&C Act has 
over food versus cosmetics. 11 
The FD&C Act food subchapter features provisions governing 
such specificities as bottled water and infant formula. 12 Although 
there are obvious human health and safety concerns that lead to 
regulating the food industry in this in-depth manner, 13 cosmetics do 
not garner the same relative protections. 14 
Drugs under the FD&C Act are regulated even more exhaus-
tively than food.15 The drug subchapter is divided into nine parts with 
a total of over one hundred governing provisions. 16 These again in-
clude the same three analogous cosmetics provisions, which here have 
a multitude of nuanced subsections. 17 As with food, the health and 
safety rationale behind these provisions is clear, but sharpens the con-
trast with regard to the comparative lack of cosmetics regulation. 18 
5. See id. § 362. 
6. See id. §§ 361--63. 
7. FDA Authority over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are 
FDA-Regulated, U.S. FOOD & DRUG ADMIN., http://www .fda.gov/Cosmetics /GuidanceReg 
ulation/LawsRegulations/ucm074162.htm [https://perma.ccfl'8GV-QX8W] [hereinafter 
FDA Authority over Cosmetics]. 
8 . See 21 U.S.C.A. §§ 351--60fff-7 (West 2017); see also 21 U.S.C.A. §§ 341-501-1. 
9 . See §§ 341--501-1. 
10. Id. §§ 342-43. 
11. §§ 361--63; see also§§ 341-501-1. 
12. §§ 349, 350a. 
13. See David F . Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Legislative 
History and Its Substantive Provisions, 6 L. & CONTEMP. PROBS. 2, 3 (1939). 
14. See 21 U.S.C.A. §§ 361--63 (West 1993). 
15. See§§ 351--60fff-7; see also§§ 341--501-1. 
16. See§§ 351--60fff-7. 
17. See§§ 351-53. 
18. See Cavers, supra note 13, at 3. 
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Throughout the rest of the FD&C Act, beyond the cosmetics 
subchapter, the FDA has been given the legal authority to inspect 
cosmetic facilities as well as imported cosmetics.19 This authoriza-
tion is given in tandem with the right of the FDA to also inspect 
food, drug, device, and tobacco product facilities. 20 Despite this after-
the-fact mechanism for regulation, however, the FD&C Act requires 
no pre-market approval for cosmetics or cosmetic ingredients (with 
the exception of color additives), and leaves the safety determination 
to the manufacturer. 21 As the FDA explains, "[c]ompanies and indi-
viduals who manufacture or market cosmetics have a legal responsi-
bility to ensure the safety of their products. Neither the law nor FDA 
regulations require specific tests to demonstrate [that] safety .... 
The law also does not require cosmetic companies to share their 
safety information with FDA."22 The FDA can, and does, issue non-
binding guidance documents that advise cosmetics manufacturers 
on a number of topics from general good manufacturing practices to 
more specific topics, such as the recommended maximum level of 
lead in lipstick. 2s Notwithstanding these suggestions, guidance 
documents do not confer rights on or limit manufacturers, nor do 
they give legal authority to the FDA.24 Manufacturers are still free 
to use alternative approaches as long as they do not violate the 
applicable law, in other words, the FD&C Act.25 The cosmetics in-
dustry, thus, is the party responsible for ensuring product safety, 
and no specific rules exist to establish the safety of cosmetic prod-
ucts or ingredients. 26 
This self-regulatory scheme provides the cosmetics industry with 
only a vague idea of determining a product or ingredient to be safe: 
[The] FDA has stated that "the safety of a product can be ade-
quately substantiated through (a) reliance on already available 
toxicological test data on individual ingredients and on product 
formulations that are similar in composition to the particular 
cosmetic, and (b) performance of any additional toxicological and 
other tests that are appropriate in light of such existing data 
and information."27 
19. Inspection of Cosmetics, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Cosmetics 
/ComplianceEnforcement/ucm136455.htm [https://perma.cc/7Q5A-J8ED]. 
20. See 21 U.S.C.A. § 374 (West 2017). 
21. FDA Authority over Cosmetics, supra note 7. 
22. Id. 




26. FDA Authority over Cosmetics, supra note 7. 
27. Id. (citation omitted). 
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While the FDA also conducts its own cosmetics safety research, ac-
tion is only taken against an allegedly unsafe product after that 
product has been introduced on the market and may have affected 
consumers. 28 
B. Federal Food, Drug, and Cosmetic Act Legislative History 
Delving into the legislative history of the FD&C Act reveals little 
information on the thinking behind creating such comprehensive 
regulation for food and drugs, and comparatively so little for cosme-
tics.29 Congress passed the FD&C Act in 1938 and for the first time 
created consumer protection over medical devices and cosmetics. 30 
Upon its consideration by the seventy-fourth Congress in 1935, Presi-
dent Roosevelt said ofthe then-bill: 
[i]t is time to make practical improvements. A measure is needed 
which will extend the controls formerly applicable only to labels 
to advertising also; which will extend protectwn to the trade in 
cosmetics; which will provide for a cooperative method of setting 
standards and for a system of inspection and enforcement to 
reassure consumers grown hesitant and doubtful; and which will 
provide for a necessary flexibility in administration as products 
and conditions change.31 
Roosevelt specifically called for the protection of the cosmetics in-
dustry in his special statement to Congress, yet only a few provisions 
were ultimately included.32 
The major issues surrounding the bill made no mention of the 
discrepancies in the depth and breadth of regulation between cosme-
tics and food and drugs. 33 These issues dealt primarily with the FDA's 
power to make multiple product seizures; which agency should have 
jurisdiction over food, drug, and cosmetic advertising; and judicial re-
view of regulations made by the Secretary of Agriculture. 34 Over the 
next few years the bill was debated, and in 1937, the definition of 
28. See Science & Research, U.S. FOOD &DRUG ADMIN., http://www.fda.gov/Cosmetics 
/ScienceResearch/default.htm [https://perma.cdN9Z7-2UD2] [hereinafter Science and 
Research]. 
29. See generally Cavers, supra note 13, at 2-5. 
30. Summary of NDA Approvals & Receipts, 1938 to the present, U.S. Foon & DRUG 
AD:MlN., http:/lwww.fda.gov/AboutFDAIWhatWeDo/History/ProductRegulation/Sum.m.ary 
ofNDAApprovalsReceipts1938tothepresent/default.htm [https://perma.cc14AS9-TU58]. 
31. Cavers, supra note 13, at 12-13 (emphasis added) (citation omitted). 
32. 21 U.S.C.A §§ 361-63 (West 1993); Cavers, supra note 13, at 12-13. 
33. See Cavers, supra note 13, at 13-15. 
34. Id. 
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"cosmetic'' was added. 35 The bill eventually passed in both the House 
ofRepresentatives and the Senate, and President Roosevelt signed 
it into law in June of 1938.36 Since its passage, the Act has largely 
remained the same with regard to cosmetics; a fourth section origi-
nally in the cosmetics subchapter, which directed the Secretary to 
promulgate regulations for the listing of coal tar coloring in cosme-
tics, was repealed in 1960.37 
The legislative history of the FD&C Act offers little insight into 
the reasoning for the relatively short list of cosmetics regulations. 38 
Perhaps there were simply fewer cosmetic products in the 1930s, or 
cosmetic products were not that commonplace. Regardless of the 
cosmetics statistics of the years leading up to the passage of the Act, 
in the past eighty years, the cosmetics industry has grown signifi-
cantly as new ingredients and products have been developed and 
have become more widely used. 39 The presence of such relatively ex-
tensive regulations on food and drugs in the FD&C Act still begs the 
question of why the same level of protection is not afforded to cosme-
tics, given their own health and safety implications. 40 
II. COSMETICS AND THEIR CORE USERS: WOMEN 
A. Defining "Cosmetic" and Analyzing Use 
The United States cosmetics industry boasts an annual revenue 
of over sixty billion dollars.41 The United States was considered the 
most valuable beauty and personal care market globally in 2016, 
leading North America to make up almost a quarter of the cosmetic 
market worldwide.42 The United States cosmetics industry employs 
over 63,000 people, and the industry's gross product is about $14 
billion.43 Before breaking down the statistics further to determine 
the industry's main consumer, it is imperative to understand the 
definition of "cosmetic" under the FD&C Act: 
35. Id. at 16-18. 
36. Id. at 21-22. 
37. 21 U .S.C.A. § 364 (repealed 1960). This topic is now covered in a separate general 
authority provision encompassing cosmetics as well as food, drugs, and devices. See 21 
U.S.C.A. § 379e (West 2012). 
38. See 21 U.S.C.A. §§ 361--63; see generally Cavers, supra note 13. 
39. See Important Cosmetic Industry Developments in the United States, COSM. INFO., 
http://www .cosmeticsinfo.org/cosmetics-developments [https:/lperma.cc/K5XP-S4TL]. 
40. See§§ 351-60fff-7, 361-63; see also§§ 341-501-1. 
41. Statistics & Facts on the U.S. Cosmetics and Makeup Industry, STATISTA, http:// 
www .statista.com/topics/1008/cosmetics-industry [https://perma.cc/F 45L-6C6W] [here-
inafter Statistics & Facts]. 
42. Id. 
43. Id. 
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The term "cosmetic" means (1) articles intended to be rubbed, 
poured, sprinkled, or sprayed on, introduced into, or otherwise 
applied to the human body or any part thereof for cleansing, 
beautifying, promoting attractiveness, or altering the appear-
ance, and (2) articles intended for use as a component of any 
such articles; except that such term shall not include soap.44 
227 
Products that fall into this definition include, among many others, 
such items as skin moisturizers, perfumes, lipsticks, and hair colors, 
as well as individual components of a cosmetic product. 45 Some 
products that would otherwise be included in this definition are de-
fined elsewhere in the FD&C Act as a drug, device, or dietary sup-
plement, 46 or outside of the FDA's jurisdiction altogether, as it is the 
case with soap.47 
Returning to the statistics, analyzing specific product categories 
sheds more light on who is actually consuming cosmetics. 48 Haircare 
products represent the largest part-twenty-four percent-of the 
United States beauty industry.49 Foundation sales reach over $980 
million. 50 The leading cosmetic brand is Neutrogena, and their top 
product is their makeup remover. 51 Revlon's "Beyond Natural" false 
eyelashes alone account for $3.4 million in sales. 52 Each of these 
statistics seems to represent popular products among not just con-
sumers, but women specifically. 53 
Thirty-five percent of women use one to two cosmetic products 
daily, with seventeen percent using three to four.54 Fifty-four percent 
of men, on the other hand, will not use a single cosmetic product on 
a given day.55 Women also reportedly spend more just because they 
are women, often as a result of sexual prejudice in the market. 56 A 
study observing women across the United States found companies 
charging "an unjustified markup for products marketed towards 
females .... [and] on average women pay $151 billion in extra fees 
and markups that men don't have to pay."57 
44. 21 U.S.C.A § 321(i) (West 2016). 
45. FDA Authority over Cosmetics, supra note 7. 
46. ld. 
47. Soap: FAQs, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Cosmetics/Products 
Ingredients/Productslucmll5449.htm [https://penna.cc/E5L8-GBL8]. 
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Specific statistics and research tend to support the data's con-
clusion that women consume cosmetic products more than men 
overall. 58 A study conducted by the Centers for Disease Control and 
Prevention (CDC) in 2000 found that a wide variety of cosmetic 
products contained phthalates, which were largely not labeled in the 
products' ingredient lists.59 The CDC researchers discovered wide-
spread exposure throughout the population-with adult women show-
ing higher levels of phthalate metabolites from the use of personal 
care products. 60 Moreover, research has shown a significant relation-
ship between phthalate levels in a pregnant woman's body and 
subsequent adverse effects on male reproductive development.61 
Further, African-American women spend eighty percent more 
per capita on cosmetic products than any other ethnic group, mainly 
on haircare products such as relaxers.62 It appears evident that 
women, who tend to have longer hair than men, would be more likely 
to use such products for styling or simply easier maintenance.63 
Even products that are more gender-neutral on their face show 
a discrepancy in use between women and men. 64 A CDC study from 
2013 showed that sunscreen, used to mitigate ultraviolet radiation 
exposure and help prevent skin cancer, is used by women double the 
amount when compared to men's usage.65 Over twenty-nine percent 
of women said that they regularly use sunscreen on their face and 
exposed skin, whereas only fourteen percent of men reported the 
same.66 More women admitted to using sunscreen regularly only on 
their face (about forty-three percent) versus on other exposed skin 
(thirty-four percent).67 In men, these numbers were approximately 
eighteen and twenty percent, respectively.68 
58. Rajiv Shah & Kelly E . Taylor, Concealing Danger: How the Regulation of Cos-





62. ld. at 212. 
63. Merrill Fabry, Now You Krww: How Did Long Hair Become a Thing for Women?, 
TIME (June 16, 20 16), http:l/time.com/4348252/history-long-hair [https://perma.cd273J 
-KNA9]. 
64. See Study: Most Americans Don't Use Sunscreen, AM.ACAD. DERMATOLOGY (May 19, 
2015), http://www.aadorg/media/newsreleaseslstudy-most-americans-don-t-use-sunscreen 
[https://perma.cc/P8RY-4XQT] [hereinafter Study: Most Americans]. 
65. Id. Although sunscreen is actually defined as a drug under the FD&C Act, this 
still offers proof that cosmetics (and products like sunscreen that would otherwise fit the 
definition of"cosmetic" in the absence of their own specific provisions elsewhere in the 
FD&C Act) are used by more women than men. See 21 U.S.C.A. § 360fff (West 2014). 
66. Study: Most Americans, supra note 64. 
67. ld. 
68. ld. 
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"Women may be more likely to use sunscreen on the face be-
cause of the anti-aging benefits, or because of the many cosmetic 
products on the market that contain sunscreen."69 In further support 
of this notion, the study also discovered that men (at almost forty-four 
percent) were more likely than women (at twenty-seven percent) to 
never use sunscreen on their face, and at similar percentages with 
regard to other exposed skin.70 Despite women's and men's respec-
tive reasons for sunscreen use or non-use, this study shows that 
even products marketed to the general population (as opposed to 
just women), for something gender-nonspecific like skin cancer pre-
vention, are still more likely to be used by women. 71 
Looking back to the FD&C Act, food and drug consumption and 
usage certainly seem more equally spread amongst the genders: both 
women and men consume food and use drug products and medical 
devices. 72 It is true that some drugs are specifically produced for use 
by only one gender (e.g., birth control); however, the outstanding dif-
ference between these gender-specific drugs and cosmetic products 
is that such drugs are regulated under the FD&C Act, while cosme-
tics are not. 
B. Cosmetics Affect Women More Than They Affect Men 
Cosmetics usage has the potential to affect women (adversely, as 
well as beneficially) on a larger scale than men. Health concerns may 
arise primarily because cosmetic products often wind up ingested or 
absorbed into the body.73 Perhaps the most obvious example of this 
is lipstick, trace amounts of which undoubtedly get inadvertently 
ingested when the wearer eats, drinks, or licks her lips-the aver-
age woman is said to "eat" one to three tubes of lipstick per year, 
equating to a shocking four to nine pounds in her lifetime. 74 Tracing 
the history of lipstick helps to shed some light on its overall lack of 
regulation, as well as its potential impact. 75 
At the beginning of the twentieth century, lipstick in America 
began to not only symbolize femininity, but also female emancipation, 
as suffragettes endorsed the product. 76 American women would 
69. Id. (citation omitted). 
70. Id. 
71. Id. 
72. See Tammy Worth, Drugs That Work Directly in Women and Men, EVERYDAY 
HEALTH (Feb. 19, 2015), http://www.everydayhealth.com/news/drugs-work-differently 
-woman-than-man [https:/lperma.cc/D26P-WSYF] . 
73. Sarah E. Schaffer, Reading Our Lips: The History of Lipstick Regulation in Western 
Seats of Power, 62 FOOD DRUG L.J. 165, 222 (2007). 
74. Id. 
75. Id. at 165. 
76. Id. at 176. 
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publicly apply their lipstick, often in a noticeable red hue, with the 
intent of appalling men and reclaiming the product as one of female 
rebellion.77 Lipsticks first appeared in their modern tubes in 1915, 
making them more readily available, but neither federal nor state 
safety laws examined issues with lipstick preservation or their con-
tinued use. 78 Despite the absence of cosmetics regulation under the 
Pure Food and Drugs Act of 1906 (the predecessor to the FD&C Act), 
some states considered limiting lipstick's use, though not for the 
reasons one would hope 79: 
New York's Board of Health considered banning lipstick out of 
concern that it might poison the men who kissed women wearing 
it. A bill introduced in the Kansas legislature's 1915 session would 
have made it a misdemeanor for any woman under age 44 to wear 
cosmetics if "for the purpose of creating a false impression."80 
These sexist proposals did little to address the safety implications 
of women's use oflipstick, but were instead concerned only with how 
such use would affect men. 81 
The passage of the FD&C Act in 1938 opened the door for cos-
metics regulation in its grant of jurisdiction to the FDA.82 The Act's 
limitations on poisonous or deleterious substances, as well as on 
false or misleading claims, allowed progress to be made in the after-
math of its enactment, and prompted some state regulation as 
well.83 Further regulations involving labeling and color additives 
were legislated over the next several decades. 84 The FDA attempted 
to regulate lipstick itself as a color additive, which would require 
FDA pre-approval before sale, but the Second Circuit Court of Ap-
peals struck this down as exceeding the FDA's statutory authority.85 
Self-regulation has ruled since the late twentieth century, with 
the FDA believing cosmetics to be of the lowest concern in terms of 
being hazardous.86 Concerns about shortcomings of industry self-
regulation were not addressed by the FDA, it was only addressed in 
some state legislatures.87 During the 1990s, the FDA grappled with 
77. Id. 
78. Id. at 177. 
79. Schaffer, supra note 73, at 177. 
80. Id. at 177-78 (citation omitted). 
81. Id. 
82. Id. at 182. 
83. Id. at 182-85. 
84. Id. at 189-91. 
85. Schaffer, supra note 73, at 193-94. 
86. Id. at 203-04. 
87. Id. at 204. 
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(a) conflicting views of allowing the cosmetics industry to self-regulate 
based on cosmetics' low risk, and (b) ending self-regulation based on 
industry reporting problems--the cosmetics industry had only been 
reporting problems at the rate of one in every fifty reports. 88 Today, 
the FDA can still only regulate pre-market with regard to adulter-
ated or misbranded cosmetics and can test and analyze products 
post-market to address safety concerns. 89 
In December 2016, the FDA issued non-binding draft guidance 
on the recommended maximum level oflead in cosmetic lip products 
and externally applied cosmetics. 90 This guidance stemmed from the 
2007 Campaign for Safe Cosmetics' (CSC) finding of lead in a small 
selection of lipsticks on the market.91 In response, the FDA exam-
ined lead levels not only in lipsticks, but in other externally applied 
cosmetics such as mascara, eye shadows, lotions, and powders. 92 The 
results showed that more than ninety-nine percent of the cosmetics 
surveyed had less than ten parts per million (ppm) lead. 93 The FDA 
concluded that because it seemed that the vast majority of manufac-
turers could keep lead levels in their products at ten ppm or below, 
this number should be the threshold amount. 94 They further deter-
mined that up to ten ppm lead in cosmetic products does not pose a 
health risk to the (specified as female) user: 
Exposure to lead from lipstick is mainly by swallowing, such as 
after a consumer licks her lips, so we used the same approach for 
cosmetic lip products that we use to estimate exposure to lead 
from food. We determined that exposure to 10 ppm lead from 
incidental ingestion of cosmetic lip products is very small and 
cannot be measured in routine blood testing.96 
Exposure to lead from other cosmetics is by absorption through the 
skin, but the amount absorbed is very small.96 This means that 
exposure to lead from a product such as eyeshadow or body lotion is 
88. Id. at 211. 
89. FDA Authority over Cosmetics, supra note 7. 
90. U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: LEAD IN COSMETIC LIP 
PRODUCTS AND EXTERNALLY APPLIED COSMETICS: RECOMMENDED MAxiMUM LEVEL (Dec. 
2016), http:/fwww.fda.gov/Cosmetics/GuidanceRegulation/GuidanceDocumentslucm452623 
.htm [https://perma.cc/UN38-N79T] [hereinafter DRAFT GUIDANCE FOR INDUSTRY]. 
91. Limiting Lead in Lipstick and Other Cosmetics, U.S. FOOD & DRUG ADMIN. 
(Feb. 22, 2018), http:/fwww.fda.gov/Cosmetics/Productslngredients/Producta/ucml37224 




95. Id. (emphasis added). 
96. Id. 
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even lower than exposure to lead from a lipstick or other lip cosme-
tics; moreover, it cannot be measured in routine blood testing. 97 
Unaddressed by the FDA, however, is whether women using a 
combination of many externally applied cosmetics with a trace amount 
of lead increases chances of a health risk. 98 It is also imperative to 
recall that FDA guidance documents do not establish legal remedies 
and merely reflect the FDA's current stance on a topic.99 
Despite health and safety concerns brought to the FDA's atten-
tion by individuals and organizations such as esc, because these 
examinations in response are conducted post-market, it is inevitable 
that some products fall through the cracks and continue to be sold 
and used.100 In 2004, Jessica Simpson debuted her "Dessert Beauty'' 
collection, which included lip glosses, lotions, and fragrances, all mar-
keted as edible.101 Pink and glittery Dessert Beauty advertisements 
declared "It's a fragrance. It's a flavor." and "Be fabulously :flavored."102 
Although it is the Federal Trade Commission (FTC), not the FDA, 
that has jurisdiction over both food and cosmetics advertising, 103 no 
lawsuit was filed alleging adulteration or misbranding as either a 
food or cosmetic product, nor was a health and safety concern brought 
to the FDA.104 The line was discontinued years later following intel-
lectual property lawsuits alleging patent and copyright infringements, 
but one must wonder how safe it really was for female customers to 
"eat" these products.105 
Beyond the safety fears of ingesting lipstick, a myriad of cosme-
tics health and safety concerns exist with the increased potential to 
affect women as cosmetics' core consumers. For instance, Keratin 
hair-straightening treatments can contain formaldehyde, a known 
carcinogen and eye, nose, throat, skin, and lung irritant.106 These 
97. Limiting Lead in Lipstick, supra note 91. 
98. Seeid. 
99. DRAFT GUIDANCE FOR INDUSTRY, supra note 90. 
100. FDA Authority over Cosmetics, supra note 7. 
101. Tori Telfer, Whatever Happened to Jessica Simpson~ Dessert Beauty Line? A Bunch 
Of Lawsuits, Apparently, BUSTLE (Aug. 28, 20 14), https:/lwww.bustle.com/articles/37714 
-whatever-happened-to-jessica-si.mpsons-dessert-beauty-line-a-bunch-of-lawsuits-appar 
ently [https://perma.cd95HP-S6JT]. 
102. Dessert Perfume-Jessica Simpson, CELEBRITY SENSATION, http://www.celebrity 
scentsation.com/celebrity-perfumes/musicians/jessica-simpson/dessert-perfume 
[https://perma.cdC466-JNME]. 
103. Advertising FAQ'S: A Guide for Small Business, F.T.C., http://www.ftc.gov/tips 
-advicelbusiness-center/guidance/advertising-faqs-guide-small-business [https://perma 
.cc!KH7G-3CCJ]. 
104. Telfer, supra note 101. 
105. ld. 
106. Anastasia De Paz, Note, The Cosmetic Regime Needs a Makeover: Advocating to 
Empower the FDA Through the Safe Cosmetics Act of 2011, 31 TEMP. J. SCI. TECH. & 
ENVTL. L . 337, 340 (2012). 
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treatments have been found to contain formaldehyde even when 
labeled formaldehyde-free, but it is not illegal under the FD&C Act 
to manufacture and sell formaldehyde-containing cosmetics.107 Indus-
try self-regulation can also be misleading, as products are deemed 
safe only in accordance with short-term side effect studies that do 
not include data regarding continued product use over a long or 
specific developmental period of time (e.g., puberty).108 
Continued cosmetics usage logically results in continued ingestion 
and/or absorption of their ingredients: 
Cosmetics that are applied to the skin will be absorbed. What is 
absorbed will be stored in fatty tissue. Studies show that 
women's bodies store chemicals cumulatively more effectively 
than men's bodies, placing women at greater risk. While expo-
sures to an individual chemical in a single personal care product 
may not cause harm, the average American woman uses 12 per-
sonal care products per day exposing her to approximately 126 
unique chemicals. 109 
Other chemicals regularly used in cosmetic products, such as pro-
gesterone and estrogenic chemicals, are also dangerous to women, 
posing harm during puberty and pregnancy and increasing the risk 
for breast cancer. 110 Biological differences in combination with simply 
using more cosmetic products more frequently over long periods of 
time, place women at a heightened health and safety risk with very 
little federal legal recourse. 111 
C. Adversely Affected Women Currently Have Limited Options in 
Seeking Legal Recourse Without Federal Cosmetics Regulation 
Since the FDA can only take legal action over products alleged 
to be adulterated or misbranded, it cannot issue a mandatory prod-
uct recall or seizure upon receipt of adverse reports. 112 Furthermore, 
when consumers make adverse product reports to the manufacturer, 
the manufacturer is not legally required to send these or other 
reports of adverse events to the FDA.m This roadblock results in 
107. Id. 
108. Id. at 340-41. 
109. Id. at 341. 
110. Id. 
111. Id. 
112. FDA Information for Consumers About WEN by Chaz Dean Cleansing Condi-
tioners, U.S. FOOD & DRUG ADMIN. (Nov. 3, 2017), http://www.fda.gov/Cosmetics/Products 
lngredients/Products/ucm511631.htm [https://perma.cc/VD8X-B5NT] [hereinafter FDA 
Information for Consumers]. 
113. Id. 
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class action personal injury lawsuits against the manufacturer, but 
without accompanying FDA-sanctioned consequences. 114 
In the case of Friedman v. Guthy-Renker, LLC, plaintiffs brought 
a class action suit against WEN by Chaz Dean, Inc., the brand, and 
Guthy-Renker, the manufacturer, alleging hair loss and scalp irrita-
tion resulting from the use of WEN haircare products.115 All but one 
claim (for breach of warranty) were brought under California law, 116 
absent the ability to seek an injunction from the FDA to stop the 
production or sale of this product. 117 Defendants continued to stand 
behind the safety of their products, as WEN "has not been proven to 
cause hair loss to consumers, nor has it been legally determined 
that any advertising of the [p]roducts was false or misleading."118 
Despite the defendants' assertions and to avoid the costs of litiga-
tion, the case resulted in a settlement, which was granted prelimi-
nary approval by the United States District Court for the Central 
District of California in 2016.119 An order granting final approval 
and a final settlement judgment were granted in August 2017, with 
several subsequent appeals filed a month later. 120 
Even if these affected women ultimately receive a settlement 
payment, their suffering was likely much more distressing than if the 
victims were men.121 "Hair loss in women can be absolutely devas-
tating for the sufferer's self image and emotional well being. Unfor-
tunately, society has forced women to suffer in silence. It is considered 
far more acceptable for men to go through the same hair loss pro-
cess."122 Societal norms have created an environment in which female 
hair loss results in psychological damage, that can be so emotionally 
taxing in a way that may eventually affect physical health.123 
Whether physical, mental, or both-health issues arising from the 
use of cosmetic products can and do affect women in a more signifi-
cant way than they affect men. Women, as the primary consumers 
of cosmetic products, ultimately use these products at a greater rate 
114. See, e.g., WEN HAIR CARE CLASS ACTION OFFICIAL SETTLEMENT WEBSITE, http:// 
www.wenclassaettlement.com [https://perma.cd85VP-LXLM] [hereinafter WENHAm CARE]. 
115. Friedman v. Guthy-Ren.ker, LLC, No. 2:14-cv-06009-0DW(AGRx), 2016 U.S. Dist. 
LEXIS 149900, at *2--3 (C.D. Cal. Oct. 28, 2016). 
116. Id. at *4. 
117. FDA Information for Consumers, supra note 112. 
118. WEN HAIR CARE, supra note 114. 
119. Friedman, 2016 U.S. Dist. LEXIS 149900, at *3, *29. 
120. News, WEN HAIR CARE CLASS ACTION, http://www.wenclasssettlement.com/News 
[https://perma.cdQT2A-FYBS]. 
121. See generally Women's Hair Loss: Introduction, AM. HAIR Loss AsS'N, http:// 
www.americanhairloss.org/women_hair_loss/introduction.asp [https://perma.cc/X9DP 
-ZEHM] [hereinafter Women's Hair Loss]. 
122. Id. 
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than men. 124 A greater percentage of women than men report regu-
larly using even gender-neutral products like sunscreen. 125 On the 
other end of the product spectrum, lipstick, a socially female-specific 
cosmetic, gets inadvertently ingested but has no federal ingredient 
requirements or limitations. 126 Other products pose health concerns 
to women simply due to biological differences, such as women's pre-
disposition ofhigher chemical retention in fatty tissue. 127 Still, more 
products may cause adverse effects that are more emotionally devas-
tating to women than they would be to men, which, in turn, can also 
affect their physical health.128 Overall, cosmetics affect women, and 
so does the lack of federal cosmetics regulation under the FD&C Act. 
III. THE LACK OF FD&C ACT REGULATION OVER COSMETICS 
HAS A DISPARATE IMPACT ON WOMEN 
The ways in which cosmetics affect women specifically cause the 
FD&C Act to have a disparate impact on women as a class. "Dispa-
rate impact'' is defined as "[a]pparently neutral behavior that has 
a discriminatory e:ffect."129 A disparate impact claim has no requisite 
intent and may be established even if the law is facially nondiscrim-
inatory.130 The FD&C Act is clearly neutral on its face; there are no 
provisions which apply or grant protections to only males or only 
females. 131 But due to the overall lack of cosmetics regulation under 
the Act, and for the concerns set forth in Part II of this Note, the Act 
effectually has a disparate impact on women. 1s2 
Equal protection is not a novel issue for the FDA.m In the 
clinical trial context, FDA guidelines from 1977 "recommended the 
exclusion of women of childbearing potential from early phase drug 
trials."1s4 Over a decade later, the FDA modified this guidance with 
124. See Exposures Add Up-Survey Results, EWG's SKIN DEEP COSM. DATABASE, 
http:/lwww.ewg.org/skindeep/2004/06/15/exposures-add-up-survey-results/#.W4xRri2 
ZPBJ [https://perma.cc/JJBV-7Q7F]. 
125. Study: Most Americans, supra note 64. 
126. See Limiting Lead in Lipstick, supra note 91. 
127. De Paz, supra note 106, at 341. 
128. See, e.g., Women's Hair Loss, supra note 121. 
129. Disparate Impact, THE WOLTERS Kl..UWER BOUVIER LAW DICTIONARY DESK EDI-
TION (20 12). 
130. Id. 
131. See 21 U.S.C. §§ 301-399h (2012). 
132. See discussion supra Part II. 
133. See WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING 
WOMEN IN CLINICAL STUDIES 146 (Anna C. Mastroianni et al. eds., 1994), https:/lwww 
.ncbi.nlm.nih.gov/pubmed/25144026 [https://perma.cc/TGE7 -PPVZ] [hereinafter WOMEN 
AND HEALTH RESEARCH]. 
134. Id. at 147. 
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the 1993 Guideline for the Study and Evaluation of Gender Differ-
ences in the Clinical Evaluation of Drugs. 135 This recommended that 
the subjects in a clinical study reflect the actual population that will 
receive the drug once it is on the market.136 Although this new guide-
line advocated, but did not require, that women participate in the 
early stages of drug trials, it created an expectation of identifying 
whether a gender difference exists in response to a drug, and, if so, 
the basis of that gender difference. 137 The inclusion of women in 
clinical studies would help to indicate post-market effects on women 
that were never before evaluated pre-market, such as response to a 
drug based on the varying hormone levels of the menstrual cycle. 138 
Additionally, female inclusion would open the door to recognizing 
the need for further testing on specific subsets of the population to 
determine the drug's safety and efficacy.139 
The Supreme Court has not decided an equal protection chal-
lenge to a demographic restriction in clinical trials, but "legal ex-
perts maintain that research policies that result in the exclusion of 
women as a class, whether on their face (with explicit exclusionary 
language) or in effect (because they result in disproportionate par-
ticipation of men and women), may be found to contradict the equal 
protection clause."140 The Supreme Court's holding that the equal 
protection clause of the Constitution restricts the government's (and 
its agencies') right to treat similarly situated people differently 
supports this theory.141 
Critically, a law being unconstitutional and a law having a 
disparate impact are not the same. 142 The Supreme Court in Feeney 
held that a neutral law may have a disproportionate, adverse effect 
on a minority but requires a discriminatory intent to be unconstitu-
tional.143 The Court further held that "[c]lassifications based upon 
gender, not unlike those based upon race, have traditionally been 
the touchstone for pervasive and often subtle discrimination."144 
This Note does not purport to argue that the FD&C Act and its lack 
of cosmetics regulation are unconstitutional because its drafters 
intended to adversely discriminate against women; the FD&C Act 
135. Id. at 139. 
136. Id. at 139--40. 
137. Id. at 140. 
138. Id. 
139. WOMEN AND HEALTH RESEARCH, supra note 133, at 140. 
140. Id. at 146 (emphasis omitted). 
141. See id. 
142. Pers. Adm'r of Mass. v. Feeney, 442 U.S. 256,272 (1979). 
143. Id. 
144. Id. at 273. 
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instead has a disparate impact on women in its application that 
must be remedied. 
IV. THE COSMETICS INDUSTRy'S CURRENT SELF-REGULATION 
REGIME DOES NOT CURE THIS DISPARATE IMPACT; THUS, 
ADDITIONAL FEDERAL REGULATION Is NEEDED 
One could argue that the cosmetics industry's current self-
regulatory scheme does not require federal intervention because the 
FDA's current authority is sufficient and has worked since the FD&C 
Act's enactment.145 Although the industry is ultimately responsible 
for product safety, the FDA can advise by issuing guidance documents 
and monitor once a product has been flagged as unsafe. 146 In regards 
to cosmetic testing, the FDA has consistently advised the industry 
to use whatever testing necessary to ensure product safety. 147 The 
FDA also monitors the conduction of product recalls, and may even 
request a recall if a company refuses to remove dangerous products 
from the market.148 However, unlike in the past, much of the indus-
try seems to agree that this is not enough. 149 A study conducted from 
2004 to 2016 found that consumers and healthcare providers re-
ported an average of 400 cosmetics-attributed adverse events per 
year.15° Consumer complaints more than doubled from 2015 to 2016 
due to the WEN haircare product events. 151 Most notably, the num-
ber of cosmetics-related adverse events reported to the FDA was 
considerably lower than those reported for drugs and medical de-
vices. 152 Cosmetics manufacturers are not required to disclose to the 
FDA any complaints they receive, which likely explains this discrep-
ancy.153 "[U]nder existing law, the [FDA] could take action against 
[a] company only if it could prove a product had been mislabeled or 
contaminated. If the product turns out to be dangerous but legal, 
the government has no recourse."154 
145. See, e.g., Pepper Hamilton ILP, Regulation of Cosmetics: Is Increased FDA Over-
sight on the Horizon?, LEXOLOGY(Nov. 28, 2017), http://www.lexology.com/library/detail 
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This lack of oversight in effect puts the burden on the consumer 
to investigate which ingredients may be harmful to her.155 ''It is a situ-
ation in which the old adage 'let the buyer beware' truly applies."156 
Furthermore, many effects of certain ingredients on human-namely, 
women's-health were not known in 1938; thus, the law as it stands 
does not reflect the past eighty years' breadth of know ledge.157 Three 
notable pieces of legislation-the Personal Care Products Safety 
Act, the Safe Cosmetics Modernization Act, and the FDA Cosmetic 
Safety and Modernization Act of 20 17-have been introduced over 
the past several years in both the House and the Senate aiming to 
tackle the disparate impact on the female consumer, albeit to vary-
ing degrees. 108 
A. Personal Care Products Safety Act 
Introduced by Senators Dianne Feinstein and Susan Collins in 
2015 and reintroduced in May 2017, the Personal Care Products 
Safety Act (PCP SA) would broaden FDA authority over cosmetics in 
a number ofways.159 The bill requires the FDA to evaluate a mini-
mum of five ingredients per year to determine their safety and ap-
propriate use, going so far as to dictate the first five ingredients to be 
analyzed: four preservatives and one color additive.160 PCPSAoutlines 
the standard of review for this requirement as "determining whether 
there is 'adequate evidence to support a reasonable certainty among 
competent scientists that the ingredient is not harmful."'161 
PCPSA also grants the FDA the authority to establish condi-
tions for safe use of an ingredient, order recalls of cosmetics posing 
safety risks, and conduct cosmetics safety activities funded by cos-
metics companies' required fees. 162 Cosmetics facilities would have 
to register with the FDA, and companies would also be required to 
submit annual reports of all adverse events.163 An express preemp-
tion provision in the bill would prohibit states from imposing regula-
tions different from or in addition to the FDA's.164 
155. Should the FDA Crackdown on the Cosmetics Industry?, Om. FOR PLAsTIC SURGERY 
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Response to PCPSA has been positive from many of the big names 
in the industry.165 Johnson & Johnson created a webpage entitled 
"Consumer Confidence Is More Than a Formula" to outline its sup-
port for PCPSA.166 The webpage names the key features of PCP SA 
to highlight the goal of"bringing peace of mind to consumers."167 A 
Johnson & Johnson lobbyist touted PCPSA as "'supported by a vast 
and diverse group of people and groups who all want the same 
thing-cosmetic regulations that best serve the public health and 
give consumers confidence in the products and ingredients they 
choose for their families.' "168 Proctor & Gamble reiterated its sup-
port for PCPSA even after the introduction of a second cosmetics 
reform bill in the Senate in October 2017.169 Other major environ-
mental, consumer, and health groups, including the American Cancer 
Society, have also supported the bill.170 
Others, including the Independent Cosmetic Manufacturers and 
Distributors (ICMAD) and cosmetics company Mary Kay, have criti-
cized PCPSA as "overreaching'' and failing to provide a clear uniform 
safety standard.171 The beauty care trade association, to which WEN 
haircare's distributor belongs, has also lobbied against PCPSA.172 
"The fight has pitted smaller independent players against the giants 
of the beauty products industry, which back the proposed regula-
tions, seeing them as an avenue toward regaining public trust, and 
have the size and muscle to comply with them.'ma In response to this 
backlash, the most recent version of PCPSA added a provision ex-
empting small businesses (those averaging less than $500,000 in 
gross sales over 3 years as well as home-based businesses averaging 
less than $1 million) from its requirements.174 
B. Safe Cosmetics Modernization Act 
In response to smaller companies' backlash against PCPSA, 
Representative Pete Sessions introduced competing legislation in 
165. See Lipton & Abrams, supra note 154. 
166. Consumer Confidence is More Than a Formula, JOHNSON & JOHNSON, http://www 
.cosmeticsreform.com/index.html [https://perma.cciZN87-ZQZU]. 
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the House in late 2015, and again in early 2017.175 The Cosmetic 
Modernization Amendments, also referred to as the Safe Cosmetics 
Modernization Act (SCMA), 176 establishes similar requirements to 
PCPSA.177 The key difference for PCPSA critics lies in SCMA's grant 
of authority for the FDA to establish exemptions to the bill's re-
quirements "for ... efficient and cost-effective implementation."178 
ICMAD opposes PCPSA, claiming that it would place too large 
a burden on small businesses, would not provide reasonable national 
uniformity, and would stifle industry innovation.179 ICMAD instead 
"strongly supports" SCMA, which asserts that it would modernize 
current FDA cosmetics regulation while supporting small businesses 
and innovation. 180 While PCP SA would allow the FDA to collect ap-
proximately twenty million dollars in annual fees from cosmetics 
companies to help cover the cost of the mandatory safety testing on 
at least five ingredients per year, SCMA does not grant the author-
ity to order recalls or collect industry fees for safety evaluation. 181 
SCMA purports to cure the issue of national uniformity by 
remaining consistent with the Safe and Accurate Food Labeling Act 
and the Micro bead-Free Waters Act of 2015.182 "Unlike the Personal 
Care Products Safety Act, [SCMA] creates transparency in all health 
and safety decisions related to cosmetics and increases consumer 
protections. It does all this without overburdening small businesses 
or stifling the innovation that is the lifeblood of our industry."183 
C. FDA Cosmetic Safety and Modernization Act of 2017 
In October 2017, Senator Orrin Hatch introduced another piece 
of federal cosmetics oversight legislation, which, like SCMA, addres-
ses existing concerns with PCP SA. 184 This bill, known as the FDA 
175. See Cosmetic Modernization Amendments of2017, H.R. 575, 115th Cong. (2017); 
see also ICMAD's Statement on Support of Legislation to Modernize the FDA's Oversight 
Over Cosmetics, lNDEP. COSM. MANuFACTURERS AND DISTRIBUTORS (Aug. 15, 20 16), http:// 
icmad.org/advocacyllegi.slative-advocacy-program [https://perma.cc/Y5ZL-RZBL] [herein-
after ICMAD's Statement]. 
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Cosmetic Safety and Modernization Act (referred to as the "Hatch 
bill"), introduces measures for the FDA to regulate cosmetic ingredi-
ents, monitor adverse reactions, and establish good manufacturing 
practices.185 Specifically, the Hatch bill gives the FDA authority to 
accredit third-party organizations to determine chemical safety, and 
preempts state action on cosmetic chemical ingredients once the 
FDA identifies such an ingredient for review. 186 
An essential difference between the Hatch bill and PCPSA is the 
source of funding for the FDA's new work. 187 While PCPSA allows 
the FDA to collect fees from the cosmetics industry, the Hatch bill 
relies on congressional appropriations and allows for accredited third 
parties to assess safety.1881t is unclear whether congressional appro-
priations would fund such third parties or if they must bear the cost 
themselves; however, the third parties must not be financially affili-
ated with any cosmetics manufacturer or supplier.189 The Hatch bill 
thus takes the burden off the industry itself to incur regulatory costs, 
but would in turn be an additional cost to the government controlled 
by Congress. 190 
The two Senate bills also differ with regard to their burdens of 
proof for cosmetic product safety.191 Whereas PCPSA requires the 
FDA to review the safety of five chemicals per year and places the 
burden on the manufacturer to establish that chemicals in their 
products show reasonable certainty of no harm, the Hatch bill takes 
a different approach. 192 The Hatch bill authorizes chemical safety 
reviews by accredited third parties, but without any timeline or 
further specifics. 193 The ultimate burden lies with the FDA to show 
that a chemical is "not injurious" under usual use.194 
The Hatch bill enjoyed immediate support from the Personal 
Care Products Council, 195 as well as from ICMAD.196 Critiques from 
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maintained support for PCP SA, expressing concern that the Hatch 
bill would be less protective of consumers and would fail to provide 
funding to the FDA to support this new regulatory role. 197 
EWG asserts that the Hatch bill "is full ofloopholes that would 
make a broken law even worse."198 In contrast to PCPSA, the Hatch 
bill does not require (1) companies to share ingredient information 
with the FDA; (2) safety substantiation records; (3) review of a specific 
number of chemicals with any deadline; nor ( 4) disclosure of salon 
product ingredients in an effort to protect salon workers who are 
exposed to these products daily. 199 The Hatch bill requires reporting 
of only "serious" adverse effects and does not consider temporary hair 
loss to be "serious."200 Also of note, the Hatch bill would prevent states 
from enacting their own cosmetics regulations once the FDA identi-
fies a chemical for review, which would allow an administration to 
preempt state action ''by simply creating a list of chemicals."201 
EWG concludes that the Hatch bill is not bipartisan, is unsup-
ported by the industry in terms of cosmetics manufacturers and health 
groups and does not meet the principles laid out by the Personal 
Care Products Association, the industry trade association. 202 Relying 
on Congress to appropriate funding does not guarantee any amount 
for the Hatch bill to support itself.203 In contrast, PCPSA relies on 
industry funding, while still exempting smaller cosmetics compa-
nies, which would provide greater assurance that the FDA would 
have the resources to comply.204 
D. The Personal Care Products Safety Act Has the Greatest Potential 
to Address the Current Disparate Impact on Women and Should 
Thus Become the New FDA Cosmetics Regulatory Regime 
Though each piece of proposed legislation arguably contains 
pros and cons, it is clear that some form of federal cosmetics regula-
tion must be enacted. The Personal Care Products Council in its 
support for the Hatch bill stated: 
197. Id. 
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[W]e support modernizing cosmetics regulation to ensure FDA 
has the appropriate resources and administrative authority to 
continue to oversee our products. We also believe strongly that 
well-crafted, science-based reforms will enhance our industry's 
ability to innovate and further strengthen consumer confidence 
in the products they trust and enjoy every day.205 
243 
They further emphasized that they "urge Congress to move swiftly 
to pass cosmetics legislation this year."206 EWG, a staunch opponent 
of the Hatch bill and proponent of PCPSA, noted that the current 
regime is "badly broken" and should be modernized after eighty 
years offailure.207 Regardless of which bill they support, the overall 
consensus among those in the cosmetics industry favors an update 
to the FD&C Act in the name of consumer protection.208 
Overall, however, PCPSA appears to be the best equipped to 
tackle the disparate impact women face with regard to cosmetics 
regulation, or its current lack thereof. 209 For the foregoing reasons 
enumerated by EWG, PCPSA has a strong advantage over the Hatch 
bill in ultimately providing consumer assurance and protection. 210 
Returning to the WEN haircare events to illustrate an example, 
the Hatch bill only requires the reporting of"serious" adverse effects, 
which do not include temporary hair loss. 211 The women affected by 
the WEN hair products would still have no legal recourse under the 
Hatch bill separate from suing the manufacturer directly-the Hatch 
bill creates no additional protection. 212 
Similarly, the House SCMA bill "would require beauty care com-
panies to notify the F.D.A. of'serious cosmetic adverse events,' but it 
would not grant the agency the power to order a recall."213 It would 
also "broadly and retroactively'' preempt any state laws with higher 
standards, thus eliminating any additional state-specific protection. 214 
In contrast, PCPSA requires cosmetic manufacturers to report to 
the FDA any serious adverse effects within fifteen days ofbeing made 
aware, as well as to provide annual reports of all adverse effects.215 
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Even ifPCPSA, like the Hatch bill, did not define cosmetic-product-
use-induced hair loss as "serious," the FDA would still be notified of 
such events within a year.216 The affected women would therefore 
have additional remedies in the form of an FDA-authorized recall 
and government action against Guthy-Renker for failing to substan-
tiate the safety of the WEN products.217 
PCP SA also addresses the issue of cosmetics that do not produce 
adverse effects per se but can be unhealthy to use long-term, such as 
inadvertently ingesting lead-containing lipstick. 218 PCPSA "requires 
companies to share ingredient information with the FDA so that the 
agency's scientists can better evaluate how consumers are exposed to 
cosmetics chemicals."219 It also requires companies to actively sub-
stantiate the safety of their cosmetic products and maintain such 
records, allowing FDA access. 220 These active requirements on com-
panies would not only help to avoid post-market adverse events, but 
also prevent consumer use of products that only cause health issues 
over time or under certain circumstances such as pregnancy.221 
The Hatch bill lacks such ingredient information sharing and 
safety substantiation requirements.222 Without these provisions, 
companies are more likely to continue operating as they do under 
the self-regulatory system, since the FDA would not require addi-
tional safety information to be submitted from them.223 The Hatch 
bill attempts to establish good manufacturing practices, but prohib-
its the FDA "from imposing standards for which there is no current 
and generally available analytical methodology," thus limiting its 
own scope.224 SCMA, like the Hatch bill, also allows for third party 
safety substantiation for certain cosmetic ingredients, leaving the 
door open for the industry to maintain its current routine. 226 
Perhaps the most compelling argument in favor ofPCPSA is its 
source of funding.226 PCPSA would collect approximately twenty 
million dollars annually from industry-user fees.227 This funding 
would allow the FDA to cover the costs ofthe bill's requisite testing 
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of five cosmetics per year, which in turn would help manufacturers 
in the long run by effectually performing safety substantiations of 
common cosmetic ingredients for them. 228 The industry funding 
would also subsidize necessary resources for the FDA's affirmative 
power under PCPSA to act in response to adverse events. 229 
PCPSA addresses concerns that many of its opponents have 
expressed with regard to forcing small businesses to pay fees they 
cannot afford.230 It protects smaller cosmetics companies from having 
to pay these fees when their revenues are below a certain amount. 231 
It also allows a simpler registration process for companies with sales 
below two million dollars, unless they manufacture products deemed 
to be "high-risk."232 Though critics may see this as an industry burden, 
this high-risk exemption maintains PCPSA's ultimate goal of effec-
tuating consumer safety in the cosmetics market. 233 
In short, PCPSA, by mandating industry funding, ensures com-
pliance with and performance of its provisions.234 The absence of 
mandatory industry fees in both the Hatch bill and SCMA do not 
allot a clear amount to the FDA to carry out their respective provi-
sions. 235 The Hatch bill's reliance on congressional appropriation 
allows legislators to allocate FDA resources on a whim, tolerating 
potential partisan implications where funding depends on which 
political party is in power. 236 To remedy the disparate impact that 
has affected women for at least the past eighty years, the new law 
should require consistency and neutrality in its resources and 
application. Of the current proposed legislation, PCPSA is the best 
prepared to finally eliminate this bias. 
CONCLUSION 
Cosmetics are barely regulated under the FD&C Act when com-
pared to the Act's regulations governing food and drugs.237 Three 
cosmetic-specific provisions cover adulteration and misbranding, but 
provide no consumer relief allowing the FDA to regulate cosmetics 
pre-market via approval or notification mechanisms, similar to those 
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229. Seeid. 
230. Seeid. 
231. See Benesh & Faber, supra note 198; Pepper Hamilton ILP, supra note 145. 
232. Benesh & Faber, supra note 198. 
233. Seeid. 
234. Seeid. 
235. See Benesh & Faber, supra note 198; Lipton & Abrams, supra note 154. 
236. See Benesh & Faber, supra note 198. 
237. Id. 
246 WM. & MARY J. RACE, GENDER & SOC. JUST. [Vol. 25:221 
in place for certain food and drug products. 238 Nothing in the FD&C 
Act's legislative history explains this discrepancy, leaving cosmetics 
regulated today as they were eighty years ago.239 
As countless statistics demonstrate, women are more likely 
than men to purchase and use, and thus bear any potential side 
effects from, cosmetic products.240 Cosmetics wind up inadvertently 
ingested and absorbed into the body without mandated pre-market 
safety testing.241 Post-market, once an adverse effect has occurred, 
a consumer can report it to the manufacturer, but there is no guar-
antee that information will be passed on to the FDA.242 Even if it is, 
the FDA does not currently have jurisdiction to initiate a response 
and can only issue industry guidance that is not legally binding.243 
The lack of cosmetics regulation in the FD&C Act, therefore, 
has a disparate impact on women, leaving them to rely on the cos-
metic industry's self-regulatory scheme and hope that the products 
they are using truly are safe. 244 A law with an existing disparate 
impact minus such intent, does not result in unconstitutionality, but 
simply a disproportionate effect in its application. Because women 
use oosmetic products to a much greater degree than men, the FD&C 
Act has a disparate impact on women that must be addressed.246 
Despite the cosmetic industry's long history of self-regulation 
in the absence of federal regulations, this disparate impact contin-
ues to exist and requires amendments to the cosmetics subchapter 
of the FD&C Act to prevent unsafe products from entering the market 
without approval by, or at least notice to, the FDA.246 The Personal 
Care Products Safety Act and the FDA Cosmetic Safety and Mod-
ernization Act in the Senate, and the Safe Cosmetics Modernization 
Act in the House demonstrate Congress's recent efforts and intent 
to finally impose federal cosmetics regulations.247 Each bill has gar-
nered its own support and criticisms from different industry players, 
but there is a noticeable absence of a complete anti-federal regula-
tion stance.248 
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Women have used cosmetic products long before the FD&C 
Act's enactment in 1938.249 In the eighty years since, despite scien-
tific advancements, research, and adverse reports, the Act's cosmetics 
subchapter remains unaltered.250 The introduction in recent years 
of cosmetics reform bills in Congress sheds some light on the legisla-
ture's intent to finally modernize a law that has provided little, if 
any, protection to women since its inception. Hopefully soon, women 
will wash their hair and put on their lipstick with the assurance 
that they are not their products' first test subjects. 
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